Prostate-specific antigen (PSA), the target of this study, is a biomarker that specifically changes its concentration in prostate cancer; blood levels with more than 4 ng/mL PSA concentration increase the risk of prostate cancer [7,8]. This evidence concerns the gene KLK3 and prostate cancer.